{"url_path":"/sec/bbio/8-k/2026-06-26/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-026506-index.html","accession_number":"0001140361-26-026506","cik":"0001743881","ticker":"BBIO","issuer_name":"BridgeBio Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-026506-index.html","primary_entity_key":"0001743881","primary_entity_name":"BridgeBio Pharma, Inc."},"word_count":539,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nThe proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 22, 2026, with each such proposal described in the\nCompany’s definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2026 (the “Proxy Statement”).\n\nThe number of shares of common stock entitled to vote at the Annual Meeting was 195,806,242. The number of shares of common stock present or represented\nby valid proxy at the Annual Meeting was 175,706,357. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.\n\nProposal 1 - Election of Directors.\n\nThe Company’s stockholders elected the three (3) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the\n2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.\n\nDirector Nominee\n\nVotes For\n\nVotes Withheld\n\nJames C. Momtazee\n\n156,790,852\n\n4,316,018\n\nFrank P. McCormick, Ph.D.\n\n153,020,532\n\n8,086,338\n\nHannah A. Valantine, M.D.\n\n129,081,930\n\n32,024,940\n\nThere were 14,599,487 broker non-votes regarding this proposal.\n\nProposal 2 - Non-binding Advisory Vote on Compensation of Named Executive Officers.\n\nThe Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.\n\nVotes For\n\nVotes Against\n\nAbstentions\n\n152,949,577\n\n6,938,080\n\n1,219,213\n\nThere were 14,599,487 broker non-votes regarding this proposal.\n\nProposal 3 - Non-binding Advisory Vote on the Frequency of Future Non-binding Advisory Votes to Approve the\nCompensation of the Company’s Named Executive Officers\n\nThe Company’s stockholders approved, on a non-binding, advisory basis, a frequency of every 1 Year for future non-binding advisory votes to approve the\ncompensation of the Company’s named executive officers.\n\n1 Year\n\n2 Years\n\n3 Years\n\nAbstentions\n\n154,371,970\n\n5,199,700\n\n1,467,447\n\n67,753\n\nProposal 4 - Ratification of Appointment of Independent Registered Accounting Firm.\n\nThe Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for\nthe fiscal year ending December 31, 2026.\n\nVotes For\n\nVotes Against\n\nAbstentions\n\n175,420,234\n\n203,310\n\n82,813\n\nThere were zero broker non-votes regarding this proposal.\n\nProposal 5 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock\nOption and Incentive Plan\n\nThe Company’s stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan\n(the “2021 Plan”) to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares. A copy of such amendment and restatement of the 2021 Plan in the form approved by the stockholders is\nfiled hereto as Exhibit 10.1.\n\nVotes For\n\nVotes Against\n\nAbstentions\n\n132,402,786\n\n27,350,537\n\n1,353,547\n\nThere were 14,599,487 broker non-votes regarding this proposal.\n\nPursuant to the recommendation of the Board and consistent with the stockholders’ preference, the Company plans to hold future non-binding advisory votes\non the compensation of the Company’s named executive officers every year. The next required non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers will take\nplace no later than at the Company’s 2032 annual meeting of stockholders."}